USP10 in Neurological Disorders: Mechanistic Insights and Emerging Therapeutic Strategies
Annals of the New York Academy of Sciences, EarlyView.USP10 is a deubiquitinating enzyme that affects neurological diseases through multiple mechanisms, including the accumulation of toxic proteins, autophagy, and immune responses. In this review, we discuss the structure and characteristics of USP10 and summarize the role of USP10 in neurological disorders.
Celemuge +5 more
wiley +1 more source
Haematologica, 2007 The development of resistance to imatinib mesylate may partly depend on high Bcr-Abl-expression levels. Arsenic trioxide (ATO) has Bcr-Abl suppressing activity in vitro.
Heiko Konig +8 more
doaj +1 more source
CarboxyAmido-Triazole Orotate inhibits the growth of Imatinib-resistant chronic myeloid leukaemia cells and modulates exosomes-stimulated angiogenesis [PDF]
, 2012 Chronic myelogenous leukemia is a myeloproliferative disorder characterized by the t(9:22) (q34:q11) reciprocal chromosomal translocation, resulting in the expression of the chimeric Bcr–Abl oncoprotein with constitutive tyrosine kinase activity ...
ALESSANDRO, Riccardo +5 more
core
Neuropsychopharmacology Reports, Volume 46, Issue 1, March 2026.We analyzed the behavior of GPR143 gene‐deficient mice. GPR143‐KO mice displayed a mixed psychiatric phenotype. GPR143 may play a role in mesolimbic and mesocortical functions underlying sensory gating, reward, social hierarchy, cognition, and emotional regulation. ABSTRACT GPR143, originally identified as the gene product of ocular albinism 1 (OA1), a
Yoshio Goshima +9 more
wiley +1 more source
Role of STAT3 in transformation and drug resistance in CML
Frontiers in Oncology, 2012 Chronic Myeloid Leukemia (CML) is initially driven by the bcr-abl fusion oncoprotein. The identification of bcr-abl led to the discovery and rapid translation into the clinic of bcr-abl kinase inhibitors.
Rajesh R Nair +2 more
doaj +1 more source
Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance [PDF]
, 2011 BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients.
Aamer Aleem +19 more
core +1 more source
Clinical Pharmacology in Drug Development, Volume 15, Issue 2, February 2026.Abstract Asciminib is the first BCR::ABL1 inhibitor that Specifically Targets the ABL Myristoyl Pocket (STAMP) in patients with chronic myeloid leukemia. This phase 1, two‐treatment‐period, drug‐drug interaction study evaluated the effect of steady‐state asciminib on the pharmacokinetics of atorvastatin.
Matthias Hoch +9 more
wiley +1 more source
Interaction of Abl Tyrosine Kinases with SOCS3 Impairs Its Suppressor Function in Tumorigenesis
Neoplasia: An International Journal for Oncology Research, 2018 Suppressor of cytokine signaling 3 (SOCS3) is involved in Bcr-Abl–induced tumorigenesis. However, how SOCS3 interacts with Bcr-Abl and is regulated by Abl kinases remains largely unknown.
Riyue Feng +8 more
doaj +1 more source
Tumor angiogenic switch determines sustained proliferative malignant transformation in tumorigenesis and overlaps with para-inflammatory phenomena [PDF]
, 2015 Contextual BCR-ABL tyrosine kinase over-activity determines in formulated fashion the emergence of proliferation and anti-apoptosis that arise largely as derived phenomena of otherwise homeostatic mechanisms of the c-ABL gene within hematopoietic ...
Agius, Lawrence M.
core
Long-term follow-up of Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in children and adolescents managed at a single institution over a 20-year period [PDF]
, 2005 Chronic myeloid leukaemia (CML) is rare in childhood. In our Institution we managed 30 consecutive Ph+CML patients aged
DE CUIA MR +7 more
core +1 more source